RT Journal Article
SR Electronic
T1 Impacts of COVID-19 on long-term health and health care use
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.02.16.21251807
DO 10.1101/2021.02.16.21251807
A1 Skyrud, Katrine
A1 Telle, Kjetil
A1 Magnusson, Karin
YR 2021
UL http://medrxiv.org/content/early/2021/02/17/2021.02.16.21251807.abstract
AB Aim To explore impacts of mild and severe COVID-19 on acute and long-term utilization of primary care, inpatient- and outpatient specialist health care.Methods In all persons tested for the SARS-CoV-2 in Norway March 1st to November 1st 2020 (N=1 257 831), we used a difference-in-differences design to contrast the monthly health care use before and after testing, across patients with negative test (no COVID-19) and 1) positive test, not hospitalized (mild COVID-19) and 2) positive test, hospitalized (severe COVID-19). We studied all-cause- and cause-specific health care use for digestive, circulatory, respiratory, endocrine/metabolic/nutritional, genitourinary, eye/ear, musculoskeletal, mental, skin, blood and general/unspecified conditions.Results Mild COVID-19 impacted on primary care due to respiratory conditions at 0-3 months after having tested positive (786% increase). Severe COVID-19 impacted on visits due to respiratory-(337-3316% increase), circulatory-(166-205% increase), endocrine/metabolic/nutritional-(168-791% increase) as well as visits due to general/unspecified conditions (48-431% increase) in outpatient and inpatient specialist care 0-3 months after being tested. Severe COVID-19 also impacted on outpatient specialist care after 4-6 months, for respiratory and circulatory conditions (199-246% increase) and general/unspecified conditions (40% increase).Conclusion Our findings imply that mild COVID-19 does not persist to cause a need for health care beyond two months after having tested positive. Health care contacts increased the most in specialist care for those who had undergone severe COVID-19, both at 0-3 and at 4-6 months. This increase was due to respiratory, circulatory, endocrine/metabolic/nutritional and general/unspecified causes.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was funded by the Norwegian Institute of Public Health. No external funding was received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional board review was conducted, and The Ethics Committee of South-East Norway confirmed (June 4th 2020, #153204) that external ethical board review was not required.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are not publicly available